Clascoterone
Prescription skin treatment for acne that blocks the action of male hormones locally; against hair loss it is still being tested.

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Related comparisons
Clascoterone vs Pyrilutamide vs RU58841DETAILED OVERVIEW
What is Clascoterone?
Clascoterone is a prescription medicine applied to the skin, the first and so far only one approved in the United States to block the action of male hormones locally. In 2020 it was approved as a cream for acne (Winlevi). For male pattern hair loss (Breezula solution) it is still only being tested: a large, final-phase trial is under way, and it has no approval.
In sebaceous gland and hair follicle cells it occupies the binding site that DHT (dihydrotestosterone, a strong male hormone) would attach to. This reduces oil production and inflammation, and probably also the thinning of hairs in hair loss. After absorption it is quickly turned into an inactive substance, so it has little hormonal effect in the body. Two large studies confirmed its effect in acne; for hair loss the data are still being collected. The most common effects are mild redness, peeling or itching. Over a large area of skin it temporarily suppressed adrenal gland function in some patients, which returned to normal after treatment.
Development code / name
CB-03-01 · cortexolone 17α-propionate
Status
Acne: FDA-approved (Winlevi) · Hair (AGA): phase 3 investigational
Mechanism of action
Topical androgen-receptor antagonist (local anti-DHT)
Strengths
1% cream (acne) · 5-7.5% solution (investigational AGA)
Onset
4-12 weeks (acne); hair: months, during phase 3
No anecdote collected yet.
Data console
Lab data
Hebert A, Thiboutot D, Stein Gold L, et al. . Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2020;156(6):621-630..
Eichenfield L, Hebert A, Gold LS, et al. . A Phase 2b, Randomized, Double-Blind Vehicle Controlled, Dose Escalation Study Evaluating Clascoterone 0.1%, 0.5%, and 1% Topical Cream in Subjects With Facial Acne. J Drugs Dermatol. 2019;18(6):570-575..
Rosette C, Agan FJ, Mazzetti A, et al. . Cortexolone 17α-Propionate (Clascoterone) is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro. J Drugs Dermatol. 2019;18(2):197-201..
Dhillon S. . Clascoterone as a novel treatment for androgenetic alopecia. Clin Exp Dermatol. 2020;45(8):1075-1076..
Safety
Side effects, stop signs, contraindications
Side effects · 4
- Local skin reactions: mild erythema, scaling, dryness, itching at the application site; in the phase 3 acne trials local reaction rates were similar to vehicle (well tolerated).
- Signal of transient HPA-axis suppression: in a dedicated PK/safety study with large-area use a few patients showed transient, reversible adrenal-axis suppression; clinically minor but noted on the label.
- With scalp application (investigational AGA solution): local irritation, itching, flaking; long-term data are still accruing as the AGA indication is in phase 3.
- Hypersensitivity reaction (rare): contact dermatitis or more pronounced irritation; discontinue if an allergic reaction occurs.
Contraindications · 4
- Known hypersensitivity to clascoterone or any excipient.
- Broken, inflamed or infected skin: absorption and irritation may increase; withhold until it heals.
- Large body-surface, prolonged use without HPA-axis monitoring: avoid due to the (rare, transient) adrenal-suppression risk, especially in children.
- Pregnancy/breastfeeding: although systemic exposure is minimal (rapid inactivation to cortexolone), use only after benefit/risk assessment and under medical supervision due to limited data.
Related Hair & Skin
Same therapeutic category
Studies
Related research and clinical findings
Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials
Hebert A, Thiboutot D, Stein Gold L, et al.
A Phase 2b, Randomized, Double-Blind Vehicle Controlled, Dose Escalation Study Evaluating Clascoterone 0.1%, 0.5%, and 1% Topical Cream in Subjects With Facial Acne
Eichenfield L, Hebert A, Gold LS, et al.
Cortexolone 17α-Propionate (Clascoterone) is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro
Rosette C, Agan FJ, Mazzetti A, et al.
Clascoterone as a novel treatment for androgenetic alopecia
Dhillon S.
Telegram
Have a question about Clascoterone?
Educational hair and skin info from official sources (PubMed, FDA, EMA). Does NOT replace medical consultation. Talk to a dermatologist!
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.